 - Is chronically taking a strong cytochrome P450, family 3, subfamily A, polypeptide 4 CYP3A inhibitor or inducer and cannot be switched to an alternative agent at least 7 days prior to idelalisib or ibrutinib initiation that in the opinion of investigatortreating physicians precludes utilization of either Ibrutinib or Idelalisib; caution is recommended for patients taking moderate inhibitors of CYP3A 